About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Assessment of Geriatric Evaluations Impact on New AML Guidance

NCT05909501·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Colleen Redlinger
CONTACT
2152209693 [email protected]
Catherine Lai, MD
CONTACT
2153600561 [email protected]

Lead

Abramson Cancer Center at Penn Medicine

With

Bristol-Myers Squibb

Age

50–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
New diagnosis being considered for new line of treatment
Age ≥ 50 years.
Performance status 0,1, and 2

You may not be if

Inability to understand or unable to sign a written informed consent
Unable to fill out questionnaires on their own and/or do not have someone to help complete them

The record

StatusRecruiting

PhaseNo phase

Taking part100

StartedOct 2023

UpdatedOct 2, 2026

Conditions

Where1

Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States

Clareo Health | Assessment of Geriatric Evaluations Impact on New AML Guidance